Početna › Kronična mijeloična leukemija
Kliničke studije za Kronična mijeloična leukemija koje traže sudionike u SAD-u
48 studija za Kronična mijeloična leukemija traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- Houston, TX18 studija
- Seattle, WA11 studija
- New York City, NY11 studija
- Detroit, MI6 studija
- Birmingham, AL6 studija
- Philadelphia, PA6 studija
- Chicago, IL6 studija
- Baldwin Park, CA6 studija
- Portland, OR6 studija
- Nashville, TN5 studija
- Columbus, OH5 studija
- Milwaukee, WI5 studija
- Baltimore, MD5 studija
- Atlanta, GA5 studija
- Boston, MA5 studija
- Durham, NC5 studija
- Rochester, NY4 studija
- Mountain View, CA4 studija
- Cincinnati, OH4 studija
- Kansas City, MO4 studija
- Augusta, GA4 studija
- Washington, DC4 studija
- St. Louis, MO4 studija
- Sacramento, CA3 studija
- Edison, NJ3 studija
- Salt Lake City, UT3 studija
- Cleveland, OH3 studija
- Orange, CA3 studija
- Miami, FL3 studija
- Bridgeport, CT3 studija
- Buffalo, NY3 studija
- Ann Arbor, MI3 studija
- Aurora, CO3 studija
- St. Petersburg, FL3 studija
- Greenville, NC3 studija
- Minneapolis, MN3 studija
Po državama
- Alabama6 studija
- Arizona4 studija
- Colorado4 studija
- Distrikt Columbia3 studija
- Florida7 studija
- Georgia7 studija
- Illinois6 studija
- Indiana3 studija
- Kalifornija10 studija
- Kansas5 studija
- Kentucky3 studija
- Maryland6 studija
- Massachusetts5 studija
- Michigan7 studija
- Minnesota4 studija
- Missouri4 studija
- Nebraska3 studija
- New Jersey4 studija
- New York15 studija
- North Carolina8 studija
- Ohio9 studija
- Oregon6 studija
- Pennsylvania7 studija
- Tennessee5 studija
- Texas18 studija
- Utah3 studija
- Virginia4 studija
- Washington11 studija
- Wisconsin5 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
U tijeku regrutacijaFaza 1
Od 18 do 120 godina · Oba spola · Ažurirano 2. lis 2026. · NCT06904066Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
U tijeku regrutacijaOpažajna studija
Od 0 do 38 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06131801Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06817720Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
U tijeku regrutacijaFaza 1/2
Od 1 do 17 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT04925479Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07269470Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06236724Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
U tijeku regrutacijaRana faza 1
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT06398457Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
U tijeku regrutacijaFaza 1
Od 1 godina i više · Oba spola · Ažurirano 18. ruj 2026. · NCT03630991Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT01746836Study of Olverembatinib (HQP1351) in Patients With CML-CP
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 15. ruj 2026. · NCT06423911Cord Blood Transplant in Adults With Blood Cancers
U tijeku regrutacijaFaza 2
Od 21 do 65 godina · Oba spola · Ažurirano 11. ruj 2026. · NCT05884333Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
U tijeku regrutacijaFaza 2
Od 1 do 18 godina · Oba spola · Ažurirano 2. ruj 2026. · NCT07354074Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 27. kol 2026. · NCT06523556Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
U tijeku regrutacijaFaza 1
1 Day – 21 Years · Oba spola · Ažurirano 26. kol 2026. · NCT05857969Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT04838041TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
U tijeku regrutacijaFaza 1
Od 18 do 80 godina · Oba spola · Ažurirano 17. kol 2026. · NCT07302776Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
U tijeku regrutacijaFaza 2
6 Months – 65 Years · Oba spola · Ažurirano 22. srp 2026. · NCT06013423A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 6. srp 2026. · NCT01351545Allo HSCT Using RIC and PTCy for Hematological Diseases
U tijeku regrutacijaFaza 2
Do 75 godina · Oba spola · Ažurirano 6. srp 2026. · NCT05805605Asciminib Roll-over Study
U tijeku regrutacijaFaza 4
Od 7 do 100 godina · Oba spola · Ažurirano 6. srp 2026. · NCT04877522Registry of Older Patients With Cancer
U tijeku regrutacijaOpažajna studija
Od 65 godina i više · Oba spola · Ažurirano 29. lip 2026. · NCT01137825Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
U tijeku regrutacijaFaza 2
Do 60 godina · Oba spola · Ažurirano 25. lip 2026. · NCT03314974Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. lip 2026. · NCT05549661Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 10. lip 2026. · NCT07638007Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.